Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: A randomized 24-week trial

Diabetes Care

Volumn 38, Issue 12, 2015, Pages 2266-2273

  Bode, Bruce W ^a   McGill, Janet B ^b   Lorber, Daniel L ^c   Gross, Jorge L ^d   Chang, P C ^e   Bregman, David B ^f,g  

^a Atlanta Diabetes Association   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK HOSPITAL QUEENS   (United States)

^d Centro de Pesquisas em Diabetes   (Brazil)

^e MannKind Corporation   (United States)

^f SANOFI   (France)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; PIG INSULIN; TECHNOSPHERE INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; MICROSPHERE; POWDER;

ADULT; ARTICLE; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPIROMETRY; TREATMENT DURATION; TREATMENT WITHDRAWAL; WEIGHT GAIN; WEIGHT REDUCTION; ADMINISTRATION AND DOSAGE; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; FEMALE; INHALATIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; POWDER; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN ASPART; INSULIN, REGULAR, HUMAN; MALE; MICROSPHERES; MIDDLE AGED; POWDERS; YOUNG ADULT;

EID: 84955753277     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0075     Document Type: Article

References (25)

1. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997;350:1505-1510.
2. Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am 2010;39:641-654.
3. Jacqueminet S, Masseboeuf N, Rolland M, Grimaldi A, Sachon C. Limitations of the so-called "intensified" insulin therapy in type 1 diabetes mellitus. Diabetes Metab 2005;31:4S45-4S50.
4. American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care 2014;37(Suppl. 1):S14-S80.
5. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010;33:240-245.
6. Peyrot M, Skovlund SE, Landgraf R. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin 2009;25: 1985-1993.
7. Leone-Bay A, Grant M. Technosphere/insulin: mimicking endogenous insulin release. In Modified-Release Drug Delivery Technology. Vol. 2, Rathbone M, Hadgraft J, Roberts M, Lane M, Eds. New York, Informa Healthcare USA, Inc., 2008, p. 673-679 2nd ed.
8. Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of a ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol 2012;6:773-779.
9. Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther 2007;9 (Suppl. 1):S65-S72.
10. Potocka E, Cassidy JP, Haworth P, Heuman D, van Marle S, Baughman RA Jr. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol 2010;4: 1164-1173.
11. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
12. Neumiller JJ, Campbell RK, Wood LD. A reviewof inhaled Technosphere insulin. Ann Pharmacother 2010;44:1231-1239.
13. Rave K, Heise T, Heinemann L, Boss AH. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: Time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol 2008;2: 205-212.
14. Bosi E, Scavini M, Ceriello A, et al.; PRISMA Study Group. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: The PRISMA randomized trial. Diabetes Care 2013;36:2887-2894.
15. Hollander PA. Insulin detemir for the treatment of obese patients with type 2 diabetes. Diabetes Metab Syndr Obes 2012;5:11-19.
16. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: A multicentre randomised trial. Lancet 2010;375:2244-2253.
17. Skyler JS, Weinstock RS, Raskin P, et al.; Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-1635.
18. Edgerton DS, Cherrington AD, Neal DW, et al. Inhaled insulin is associated with prolonged enhancement of glucose disposal in muscle and liver in the canine. J Pharmacol Exp Ther 2009;328:970-975.
19. Ciofetta M, Lalli C, Del Sindaco P, et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999;22:795-800.
20. Del Sindaco P, Ciofetta M, Lalli C, et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998;15:592-600.
21. Tamás G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A; Insulin Aspart Study Group. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract 2001;54:105-114.
22. Davis WA, Knuiman M, Kendall P, Grange V, Davis TME; Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 2004;27:752-757.
23. Panel on Handling Missing Datain Clinical Trials; National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC, National Academies Press, 2010.
24. Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: A comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009;19:227-246.
25. Fineberg SE, Kawabata TT, Krasner AS, Fineberg NS. Insulin antibodies with pulmonary delivery of insulin. Diabetes Technol Ther 2007; 9(Suppl. 1):S102-S110.